SV

Street Verdict

Analyst Scorecard

A record of what Vishnu Kant Upadhyay said publicly, with the source. Not advice.

“Bullish on GlaxoSmithKline Pharmaceuticals, anticipating further upside towards ₹2,672-2,690, with ₹2,320 acting as strong support. The stock has shown a strong rebound above key moving averages, signaling a potential trend reversal and a breakout from a prolonged downtrend, supported by a bullish crossover among short-term EMAs.”

Vishnu Kant Upadhyay’s track record (trackable calls only): 121 graded calls · 95% CI 10–22%

GlaxoSmithKline Pharmaceuticals Ltd.BullishCalled 04 Mar 2025
Verdict:PENDING

This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.

Read the original articleSee Vishnu Kant Upadhyay’s full track record